Phialogics - About the company
Phialogics is a seed company based in Frankfurt Am Main (Germany), founded in 2021 by Pascal Oromi, Andreas Weigert, Michael J Parnham and Andreas von Knethen. It operates as a Developer of cell therapies for the treatment of auto-immune diseases. Phialogics has raised $657K in funding from HTGF. The company has 268 active competitors, including 105 funded and 63 that have exited. Its top competitors include companies like Sana Biotechnology, argenx and Dren Bio.
Company Details
Developer of cell therapies for the treatment of auto-immune diseases. The company is developing cell-type-specific immune checkpoint activators by using protein engineering of receptor ligands to generate signaling agonists that modulate the activity of immune cells.
Key Metrics
Founded Year
2021
Location
Frankfurt Am Main, Germany
Stage
Seed
Total Funding
$657K in 1 round
Latest Funding Round
Ranked
148th among 268 active competitors
Employee Count
6 as on Mar 31, 2026
Similar Companies
Legal entities associated with Phialogics
Phialogics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Phialogics GmbH CIN: HRB123475 , Germany, Active | Jun 24, 2021 | - | - |
Sign up to download Phialogics' company profile
Phialogics's funding and investors
Phialogics has raised a total funding of $657K over 1 round. Its latest funding round was a Seed round on Apr 20, 2023 for $*****. 1 investor participated in its latest round. Phialogics has 3 institutional investors.
Here is the list of recent funding rounds of Phialogics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 20, 2023 | 7130216 | Seed | 2565025 | 4473782 | 1582536 | 1237936 |
Access funding benchmarks and valuations. Sign up today!View details of Phialogics's funding rounds and investors
Phialogics' founders and board of directors
Founder? Claim ProfileThe founders of Phialogics are Pascal Oromi, Andreas Weigert, Michael J Parnham and Andreas von Knethen.
Here are the details of Phialogics' key team members:
- Pascal Oromi: Co-Founder & Chief Business Officer of Phialogics.
- Andreas Weigert: Co-Founder of Phialogics.
- Michael J Parnham: Co-Founder of Phialogics. Contact Info: 1 email address
- Andreas von Knethen: Co-Founder of Phialogics.
View details of Phialogics's Founder profiles and Board Members
Phialogics' employee count trend
Phialogics has 6 employees as of Mar 26. Here is Phialogics's employee count trend over the years:
Uncover Phialogics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Phialogics's Competitors and alternates
Top competitors of Phialogics include Sana Biotechnology, argenx and Dren Bio. Here is the list of Top 10 competitors of Phialogics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
2nd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 72/100 | ||
3rd |  Dren Bio 2019, San Carlos (United States), Series B | Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases | $156M | 69/100 | |
4th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
5th | Kiniksa Pharmaceuticals 2015, Lexington (United States), Public | Developer of therapeutics for multiple diseases treatment | $320M | 67/100 | |
6th |  Ventyx Biosciences 2018, Encinitas (United States), Acquired | Developer of therapeutics to treat autoimmune diseases | $165M | 66/100 | |
7th | Autolus 2015, London (United Kingdom), Public | Developer of engineered T-cell immunotherapy for cancer and auto-immune diseases | $181M | 65/100 | |
8th | Aclaris Therapeutics 2012, Malvern (United States), Public | Biopharmaceutical company empowering patients through therapeutic innovation in immuno-inflammatory conditions | $82M | 65/100 | |
9th | Magenta Therapeutics 2016, Cambridge (United States), Public | Developer of stem cell-based therapies for autoimmune disease, genetics blood disorders and cancer | $150M | 65/100 | |
10th | Interius Biotherapeutics 2020, Philadelphia (United States), Acquired | Developer of gene therapies for treating multiple diseases | $129M | 61/100 | |
148th |  Phialogics 2021, Frankfurt Am Main (Germany), Seed | Developer of cell therapies for the treatment of auto-immune diseases | $657K | 35/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Phialogics's competitors? Click here to see the top ones
Phialogics's Investments and acquisitions
Phialogics has made no investments or acquisitions yet.
Reports related to Phialogics
Here is the latest report on Phialogics's sector:
News related to Phialogics
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Phialogics
Explore our recently published companies
- INDI - Rajkot based, 2024 founded, Unfunded company
- Green Carbonova - Vadodara based, 2025 founded, Unfunded company
- Granth Technologies - Ujjain based, 2022 founded, Unfunded company
- Gysz Technologies - 2025 founded, Unfunded company
- Gunvesa IT Systems - Hyderabad based, 2020 founded, Unfunded company
- Gitserve Technology Solutions - Newark based, 2021 founded, Unfunded company
